Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR 2013 State-of-the-Art Clinical Symposium: Diagnosis and Management of Vasculitis

Kathy Holliman  |  Issue: August 2013  |  August 1, 2013

HBV, a de-emerging pathogen, is more complicated for patients with RA because of the threat of reactivation. Reactivation is potentially fatal but preventable, and it can occur after immunosuppression is either decreased or eliminated. This reactivation syndrome can occur in patients on low doses of methotrexate and prednisone, and it is increasingly reported in patients on biologic therapies. In the setting of HB surface antigen (HBsAg) positivity, treatment with a tumor necrosis factor inhibitor can lead to reactivation in as many as 40% of patients, Dr. Calabrese said.

All patients with a past history of HBV are at risk of reactivation, regardless of the presence or absence of serologic markers. Those at highest risk have chronic HBV infection, are HBsAg positive, and have high HBV DNA. At a bit lower risk are patients HBsAg positive and with either low or nondectable HBV DNA at baseline, he said. “My recommendation is that all patients commencing immunosuppressants and immunomodulatory therapies should be screened.”2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Diagnosing CNS Vasculitis

In his talk on CNS vasculitis, Dr. Calabrese noted that it is a treatable disease that can be diagnosed by presence of the following:

  • A neurological sign or symptom (headache, stroke, seizure) that remains unexplained after a vigorous diagnostic workup;
  • Some evidence of vascular disease in the brain, demonstrated by biopsy or angiography; and
  • Exclusion of conditions capable of producing secondary arteritis or mimicking the angiographic features of arteritis.

Correct diagnosis is based on seven “rules of thumb,” he said. The first is that there is no clinical finding or set of findings of sufficient pretest probability to secure a diagnosis of primary angiitis central nervous system (PACNS) vasculitis.3 However, some signs can be definitive and, if present, should be elevated in a differential diagnosis: elevations of cells and proteins and normal glucose for three to six weeks after chronic infection and malignancy; recurrent focal deficits; constellation of both focal signs; and diffuse cortical impairment/neurological dysfunction.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Other tips for diagnosis:

  • A lumbar puncture is the key laboratory test and should never be omitted unless there is some absolute neurosurgical contraindication.
  • Normal magnetic resonance imaging (MRI) has a very high negative predictive value. “A combination of a normal MRI and normal lumbar puncture virtually rules out this diagnosis 100% of the time,” Dr. Calabrese said.
  • No angiographic picture in the brain is 100% specific to the diagnosis of CNS vasculitis.
  • Biopsy is an imperfect diagnostic tool, with a sensitivity of 75% or 80%, but it can rule out other conditions. “A nondiagnostic biopsy that has shown no evidence of infection or malignancy often is enough for me to be confident about investing in highly immunosuppressant therapy,” Dr. Calabrese said.
  • Rule out infection and malignancy, and screen for viral infections, including HIV, HCV, and others.
  • If the patient does not respond or progresses on cyclophosphamide and glucocorticoids, suspect an alternative diagnosis rather than refractory disease.

“Ask yourself at the end of your next consult whether any of these red flags are present,” Dr. Calabrese advised. “Was the diagnosis made in the absence of a lumbar puncture? Is the diagnosis made on angiogram with a normal lumbar puncture? And if the patient is not responding to aggressive therapy, reconsider the diagnosis.”

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsMeeting ReportsVasculitis Tagged with:AC&RBehçet’s diseasecentral nervous system vasculitisVasculitis

Related Articles

    Hepatitis Reaction with Rituximab Sparks Drug Safety Alert

    January 1, 2015

    The FDA modifies rituximab prescribing information to stress risk of hepatitis B virus reactivation

    Meet the HEP C Challenge

    December 1, 2008

    Keep a hepatitis C virus infection from hindering RA treatment

    Hepatitis Virus, Rheumatic Disease Connection Explored

    July 14, 2017

    CHICAGO—Leonard H. Calabrese, DO, professor of medicine at Cleveland Clinic in Ohio, presented on emerging concepts of viral infections and rheumatic disease at the ACR’s State-of-the-Art Clinical Symposium in April. “We are at a pivotal point in rheumatology in understanding the relationship between viruses and rheumatic disease,” began Dr. Calabrese. “It’s a very exciting time.” Dr. Calabrese…

    Case Report: Diagnosing, Treating Hepatitis B-Linked Polyarteritis Nodosa

    September 17, 2019

    Hepatitis B virus (HBV) associated polyarteritis nodosa (PAN) is an increasingly rare vasculitis in developed countries due to advances in HBV vaccination and antiviral therapy. However, the condition does persist, and rheumatologists should consider it when evaluating vasculitis cases. Below, we discuss a case that illustrates the varied clinical presentations PAN can encompass. A high…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences